We are conducting this study to see if diazoxide can quickly improve depressive symptoms in people with treatment-resistant major depressive disorder (MDD).
Adults 18 to 65 years old with MDD, who are currently depressed without psychotic features will be enrolled and hospitalized for the entire study. They may be allowed short leaves.
This research aims to see if diazoxide (an enhancer of glutamate transporter function) versus placebo can rapidly improve overall major depressive symptoms in patients with treatment-resistant Major Depressive Disorder (MDD). Other goals of the study include: evaluating diazoxideâ��s effect on glutamate levels in the brain, determining whether changes in brain neurochemicals correlate with antidepressant response, and examining other biomarkers of response.
This inpatient study is assessing the effectiveness of the oral medication diazoxide (an enhancer of glutamate transporter function) versus placebo to rapidly improve hard-to-treat major depressive symptoms. The study enrolls eligible participants ages 18-65, who are diagnosed with Major Depressive Disorder (MDD), have previously failed to respond to treatment, and are free of other serious medical conditions.
This study can last up to 12 weeks and is conducted at the NIH Clinical Center in Bethesda, Maryland. There is no cost to participate. We enroll eligible participants locally and from around the country. Travel arrangements are provided and costs are covered by NIMH (arrangements vary by distance). After completing the study, participants receive short-term follow-up care at the NIH while transitioning back to a provider.
Depressed people appear to have problems regulating levels of a brain chemical called glutamate than people who are not depressed. The drug diazoxide may help regulate glutamate levels in people with depression. Researchers want to know if it can rapidly improve depression symptoms. This would help many people with depression, because most medications take a long time to work.
Objectives: To see if diazoxide can quickly improve depressive symptoms in people with treatment-resistant major depressive disorder (MDD).
Participants will be interviewed many times during the study. They will also fill out questionnaires.
Phase I will last about 4 weeks. Participants will be screened with lab tests, and psychiatric and medical history and exams. Participants will slowly go off current medications. They will be drug-free for 2 weeks.
Phase II will last about 8 to 9 weeks. Participants will be monitored, answer questions, and give blood samples. They will drink a glucose drink, give saliva samples, and have scans of their brains taken. Participants will take the study drug daily by mouth for one 3-week session. They will take a placebo daily by mouth for the other 3-week session.
There will be a drug-free period of 14 to 21 days between sessions.
For Inquiries about our studies, please contact:
Libby Jolkovsky, M.S.
Date: November 14, 2014
We are conducting this study to see if the antidepressant effects of ketamine are different in those who have relatives with alcoholism. We will also test if depressed subjects who have relatives with alcoholism respond differently to alcohol. Finally, we will see if there are unique signatures in the response to ketamine and alcohol. This may help us develop a more personal approach to depression treatment.
Glutamate-based medications including the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine result in rapid, robust and sustained (up to one week) antidepressant effects in randomized controlled trials in treatment-refractory unipolar1-3 and bipolar depression4, 5. Previous work by our group has demonstrated that a family history of alcohol dependence predicts a more robust antidepressant response to ketamine in both treatment-resistant unipolar6 and bipolar7 depression.
Recently-detoxified alcoholics and affected first-degree relatives display blunted psychotomimetic, cognitive and other neuropsychiatric effects with a subanesthetic dose of ketamine. Also, a family history of alcoholism alone predicts differential response to intravenous alcohol 8-10. Based on our prior post hoc results, we seek to prospectively demonstrate that a family history of alcohol dependence predicts a more robust antidepressant response to ketamine. We will also explore potential biomarkers of ketamineÃ¢ï¿½ï¿½s antidepressant effects in treatment-refractory depressed patients at risk of alcohol dependence (using physiological and neurochemical responses to alcohol).
We are enrolling participants ages 21-65 year old with treatment-resistant major depressive disorder without psychotic features patients in a current major depressive episode of at least moderate severity will be recruited and enrolled in this protocol. All subjects must also be free of a lifetime substance use disorder diagnosis with the exception of a nicotine or caffeine use disorder) and will be psychotropic medication-free for at least two weeks prior to the first alcohol infusion. negative subjects.
This study is a single-site, open-label protocol in psychotropic medication-free depressed subjects admitted to the Clinical Research CenterÃ¢ï¿½ï¿½s Mood and Anxiety Disorder Inpatient Research Unit (7-SE). This protocol consists of two phases (Phase I and Phase II). The first phase consists of the medication taper and drug-free period. The second phase will have three subphases: Subphase IIA infusion #1 with neurophysiological assessments), IIB alcohol infusion #2 during 7 Tesla-Magnetic Resonance Spectroscopy/Imaging (7T-MRS/I)] and IIC (subanesthetic/antidepressant dose ketamine infusion during 7T-MRS/I).
For Inquiries about our studies, please contact:
Libby Jolkovsky, M.S.
KU Wichita Clinical Trial Unit researchers are looking for adults (ages 18-65) who are suffering from depression to participate in a research study offering a cutting edge treatment. To participate the current depressive episode must last at lasted eight weeks.
Those who qualify will receive:
• Study related mental health assessments
• Physical exams
• Lab Assessments
• Study Medication
To see if you qualify, call 316-293-1833.
Trial Investigators: Dr. Matthew Macaluso and Dr. Sheldon Preskorn
Date: September 2, 2014
Have you ever suffered from depression? Voice your opinions to help improve the quality of depression care for patients across the United States.
We are researchers from Dartmouth College conducting a national survey to better understand what is important to patients when making decisions about depression treatment. Responses are anonymous and confidential. For more information or to take the survey, please go to: http://tinyurl.com/patient-treatment-survey.
Date: August 26, 2014
If you are an adult with depression and are still experiencing symptoms while taking an antidepressant, consider participating in the MOSIAC clinical research study. Visit the website to learn more and see if you may qualify.
For more information, please contact the Treatment Research Center at Rush University Medical Center in Chicago: 312-942-6597
We are looking for adolescents age 12-17 who are suffering from Major Depressive Disorder (MDD) to participate in a new Clinical Research Trial.
Purpose: To find out if an investigational drug is safe and to learn if it works for adolescents who have major depressive disorder (MDD).
FOR MORE INFORMATION CONTACT:
Kennedy Krieger Institute 443-923-3850
716 N. Broadway Baltimore, MD 21205
Robert Findling, M.D., M.B.A., Principal Investigator
NA_00086408, clinicaltrials.gov (NCT01878292)
Date: January 13, 2014
If so, please contact us about our 13-week research trial of an investigational, non-medication treatment for depression.
You may be able to participate if:
Qualified participants receive:
To learn more, please visit: http://clinicalconnection.com/PatientViewStudy21720.aspx.
Date: January 10, 2014
Childhood depression and anxiety greatly impact the lives of sufferers, taking away their ability to enjoy their childhood and making them a ghost or shadow of their former selves. We want to change this. We’re conducting ADVANCE – a clinical research study looking at how an investigational treatment called Lu AA21004 is processed in the body over time in children aged 7 to 17 years (inclusively) with depression or anxiety. Study–related treatments and procedures will be provided at no cost to you.
Please contact the study coordinator at 443-923-3850 to learn more.
Principal Investigator: Robert L. Findling, M.D. M.B.A.
Date: September 16, 2013
It may be time to consider your options.
A Clinical Research Study for an investigational medicine is enrolling people who
What is involved?
Compensation for time and travel may be provided
The study doctor can tell you if you meet all the study eligibility requirements.
Sad all the time. No energy. Feeling worthless. Trouble sleeping. Can’t focus. If you are experiencing these symptoms, this study may be right for you.
To learn more and find out if you may qualify, please visit www.DepressionStudies.com http:// www.DepressionStudies.com
Take part in a research study of an investigational medicine at no cost.
To qualify you must be :
For more information contact Premier Psychiatric Research Institute at (402) 476-6060 (Option 4) and www.PremierPsych.com.
Date: March 5, 2013
Most of us have heard of depression, but few people may know about a type of depression that appears along with psychosis (or a loss of touch with reality). Referred to as psychotic major depression (PMD), it’s a surprisingly common mental disorder that affects more than one in 100 individuals. If you or someone in your life has depressed feelings along with ideas or ways of thinking that are not true and/or see or hear things that aren’t there – it may be PMD. With PMD for example, people may hear voices telling them that they don’t deserve to live. There is a high risk of suicide for individuals with PMD so it’s critical to seek help and get treated immediately. [Note: If you have thoughts of suicide or harming yourself or others, immediately call 911 or go to your nearest hospital emergency room. You also may call a confidential suicide hotline from anywhere in the United States, 24 hours a day, seven days a week at 1-800-273-TALK (8255).]
People with PMD can and do get better with treatment. A combination of antidepressant and antipsychotic medication is an effective medication treatment.
In a new study called STOP PD II, researchers are working to understand how long people need to stay on an antipsychotic medication to prevent new episodes of psychosis after recovering from their initial symptoms. Individuals in this study will first receive a combination of an antipsychotic medication and an antidepressant medication for up to 20 weeks. They may begin in an inpatient or outpatient setting. Individuals who are nearly or fully better after up to 20 weeks will be invited to participate in a second phase of the study that lasts for up to 36 weeks.
To be eligible for the study, individuals must be 18 to 85 years old, experiencing symptoms of depression with psychosis, and not be pregnant. Study participants receive medication and medical care at no cost.
For more information about voluntary participation in this study call: Joelle M. Scanlon, PhD, at 412-246-6012
Date: January 24, 2013
Researchers in the Department of Child and Adolescent Studies at Cal State Fullerton are conducting a study to better understand how family members get along when a parent is experiencing some depressive feelings.
Participation includes a phone interview and questionnaires by mail. Families are compensated $25 for their time.
For more information, contact Marian Howland at (657) 278-1088 or firstname.lastname@example.org.
Date: January 8, 2013
The PERT (Perimenopausal Estrogen Replacement Therapy) Study is a clinical research study investigating cardiovascular health and psychological well-being during the menopause transition.
The PERT Study is enrolling two groups of women:
Eligible women will be randomly assigned (i.e., by chance) to either transdermal ERT (a skin patch containing 17b-estradiol) or placebo (a skin patch containing an inert substance). Participants will be involved in the study for 12-13 months with an optional 12 month follow-up period. Approximately 10 visits will be necessary over the initial 12-month period.
You may be eligible to participate if you are:
What will you receive if you participate?
For more information, click here www.pertstudy.com to visit our study website or please call: (919) 972-7495
Date: Nov. 2, 2012
Have you tried medications for your depression in the past which didn’t seem to help?
Are you currently taking an antidepressant but still feel low, tired, and depressed?
The Pursuit study is currently being conducted in your area to determine how safe and effective an investigational medication is for treating MDD.
We are looking for patients who:
The study will last for 20 weeks and will require approximately 20 visits to the study center so that study doctors and nurses can perform various tests and monitor how the drug affects you. Qualified participants will receive all study-related office visits, medical examinations, and investigational medication at no cost. Additionally, the cost of your currently prescribed medications for depression may be supplemented during your study participation.
For more information, click here www.majordepressionstudy.com to visit our study website or please call: 1-888-643-2056
Date: Oct. 6, 2011
The TRIADE trial is designed to assess amitifadine, a new drug being developed as a possible new antidepressant intended to reduce many of the side effects associated with typical antidepressant medications.
Who Can Participate in TRIADE?
What is amitifadine?
What can you expect if you participate in TRIADE?
The trial will be conducted at approximately 30 centers throughout the U.S., and is expected to include approximately 318 individuals.
For full enrollment criteria and to locate a center near you, please call 1 (888) 414-1808 or visit www.trialreach.com/premium/depression.
TRIADE is sponsored by Euthymics® Bioscience, Inc., maker of amitifadine.
Support NAMI to help millions of Americans who face mental illness every day.Donate today
Inspire others with your message of hope. Show others they are not alone.Share your story
Become an advocate. Register on NAMI.org to keep up with NAMI news and events.Join NAMI Today